10 customers — 22% of revenue (the year ended December 31, 2025)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2025)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2024)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2024)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2023)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 2% of revenue (the year ended December 31, 2023)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
MyMedx posted $62 million of third-quarter sales, 9% surgical growth and $2 million of adjusted EBITDA, while wound sales fell 71%; full-year guidance was updated to $250 million to $260 million. An FTC second request delays its Sonara MedTech acquisition.
MiMedx Group, Inc. reported third-quarter 2026 net sales of $62 million, down 45%, a $9 million net loss and Adj. EBITDA of $2MM, and expects 2026 net sales of $250 to $260 million.
Mimedx reported third-quarter net sales of $62 million, down 45%, a GAAP net loss of $9 million and $121 million of net cash. Its Sanara MedTech Inc. acquisition, valued at approximately $350 million, remains delayed by an FTC Second Request.
MiMedx Group, Inc. and Sanara MedTech Inc. each received a Second Request from the Federal Trade Commission on October 15, 2026 in connection with the FTC's review of their pending merger, extending the HSR Act waiting period.
